Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor ...

A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce ...

The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from Eli Lilly and Novo ...

In this week’s STATus Report, host Alex Hogan explains why weight loss pills were so much harder to develop than injectables.

Driven by high prices, lack of insurance, and a desire to lose weight, the proliferation of fake and falsified obesity drugs is prompting public health concern. Sophie Cousins reports.

A large study of data from Veterans Affairs finds that people on GLP-1 drugs were less likely to develop substance abuse disorder or overdose.

Once used by vets to anesthetize elephants, carfentanil is now an extremely dangerous illicit drug often disguised as an oxycodone tablet—and it's 100 times stronger than fentanyl.

Study of 600,000 US military veterans shows that those who took anti-obesity medications were less likely to develop some complications of substance-use disorders.

Popular weight-loss drugs such as Ozempic, Wegovy, and Mounjaro may do more than help people shed pounds. New research suggests these GLP-1 medications could also help protect the heart after a heart ...

A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.